Thank you for sharing this paper, @mayblin I’ve read everything I’ve been able to find on evenity’s impact on bone micro architecture and strength, but I had not seen this before. It’s really quite interesting.
As far as what CTX level we’ll be shooting for between doses of reclast, I don’t know at this time. I expect we’ll have that conversation at my appointment next year, which will be a year out from my first dose. Yes, if my CTX stays low enough after the first reclast dose, we’ll hold off on further infusions.
With that said, MHT may not be a long term plan for me as I have risk factors for breast cancer. I’m considering switching over from estradiol / progesterone to Duavee as there is evidence (PROMISE study) that Duavee is protective in breast tissue, and my endo believes either Duavee or estradiol will be beneficial for bone health. I just feel so improved since starting the estradiol that I’m hesitant to shake things up.
If I remember correctly, you were taking either Tymlos of Forteo - did you choose to follow up solely with MHT, or have you also taken a bisphosphonate?
I didn’t realize MHT might not be a long-term plan for you. I was thinking if your CTX stays low enough, MHT alone could potentially work without Reclast. That said, Duavee does seem like a smart option if breast cancer risk exists, and its two components likely support bone health better than a SERM alone.
I did Forteo for about 22 months, then transitioned to MHT alone (TD estradiol + oral micronized progesterone), an approach I picked up from an endo familiar with it and reinforced by member @teb success. Like you, I plan to reuse an anabolic if my DXA trends back toward –3.0; right now my lowest T-score is –2.3 at the spine.
It’ll be interesting to see how things unfold for all of us - I’ve learned so much from everyone’s experiences and am really grateful for it.